Mar. 20 at 7:32 AM
The market is shifting from speculative growth to clinical and tech execution. Here are four companies with major catalysts lined up for the remainder of this year:
$VKTX Eyes are on the readouts for their oral GLP-1 drug. This is a milestone that could position them as a buyout candidate for big pharma looking to compete with Lilly and Novo.
$DRTS A high-conviction catalyst play for the rest of the year. With Japan Approval secured, the focus is on the U.S. where recruitment for the ReSTART trial is slated to finish this month. They are also advancing trials in Glioblastoma and Prostate cancer, backed by a
$76.9M cash position.
$TSLA 2026 is a massive year for physical AI. The key catalysts are the scaling of the Robotaxi fleet and the anticipated start of Optimus Gen 3 production.
$IONQ Key catalysts for 2026 include the large-scale deployment of their AQ 64 Tempo system and aggressive revenue scaling as they transition from R&D partnerships to enterprise-grade quantum solutions.
